Reading Time: 2 minutes HMIN looked cheap these days, should we jump in and buy it? I have both MR and HMIN, and as a matter of fact, I bought some more HMIN after its disappointing earning report. My mistake. You may think because HMIN has been to $49, and now it’s trading $29.50, isn’t a big discount? Yes or
Reading Time: 2 minutes This is the report. From the Conference call, it appears they made a mistake on the announcement, I believe there was a typo on the first bullet (should be 40% rather than 24.7% YoY if exclude the large bid in 2006) My comments on the results:
Reading Time: < 1 minute Well, Xinhua Finance Media Limited XFML IPO nearly broke my heart, kind as I expected. The good thing is WR Hambrecht only allocated me 100 shares, out of 200 shares I indicated to buy. On a positive note, Mindray reported a good quarter and a good year. Here is the results. Going forward they expect
Reading Time: < 1 minute Mindray, the leading medical device maker in Shenzhen, is hiring. Here is the link in Chinese. Most are R&D positions. And some campus recruiting events. Interestingly, I noticed they are looking for Spanish, Portuguese, German and Russian speaking sales person, as shown in this ad. From this and previous company’s SEC filings we can see the company still
Reading Time: < 1 minute It appears that Mindray started new offering today. I read its SEC filings here. The insiders will sell 9,827,220 shares and the underwriter will have option to buy additional 1,474,083 shares from selling share holders. That alone won’t have dilution effect. Separately, the company filed S1 form for stock options registration. That will dilute the
Reading Time: 2 minutes (Update 12-14-2023) Came across this issue again when doing some research on the Hashicorp stock ($HCP). CEO David McJannet Confounder Armon Dadgar I assume cofounder Mitchell Hashimoto has a shell company and didn’t use his own name for the shares he traded. I didn’t dig into it: it’s not something that I feel it’s productive
Reading Time: < 1 minute I summerized its year 2005 and 2006 (low end) number here. I noted that the revenue year over year growth slowed a bit (consider first 9 months growth about 41%). This can be attribute to the continuing “anti-corruption” campaign in China hospitals. 2005 2006 YoY Rev (CNY) 1,078,573,000 1,470,000,000 36.29% Income 205,089,000 360,000,000 75.53% Earning (CNY) 2.40 3.73 55.42%
Reading Time: 2 minutes Home Inns (HMIN) and Mindray (MR) both reported their Q3 earning last week. I listened to both the conference calls. HMIN obviously did better with revenue growth: RMB 160.4 m, 106.3% year over year growth. Mindray’s revenue growth was 21.6% because of the anti-corruption campaign in Chinese hospitals. I think that growth factor determined the stock
Reading Time: 2 minutes OK, enough about the Home Inns (HMIN) and New Oriental (EDU), both of which are well known consumer brands based in Shanghai and Beijing respectively. On Sept 26, a not so well known medical device company based in Shenzhen (by Hongkong), did IPO on NYSE and it was well received by the investors. The company is Mindray Medical International, ticker symbol
Recent Comments